Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Neurocrine Biosciences Inc (NBIX) AI Forecast

Our AI detected a significant signal for Neurocrine Biosciences Inc. Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$NBIX Bullish Signal Full forecast available
Sign Up Free

Neurocrine Biosciences Inc (NBIX) Stock Forecast 2025

Neurocrine Biosciences Inc (NBIX) AI Stock Price Forecast & Investment Analysis

Neurocrine Biosciences Inc Stock Price Chart and Technical Analysis

Loading chart...

Neurocrine Biosciences Inc (NBIX) - Comprehensive Stock Analysis & Investment Research

Deep dive into Neurocrine Biosciences Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 2:58 p.m. (UTC)

Neurocrine Biosciences Inc Investment Summary

When evaluating whether Neurocrine Biosciences Inc (NBIX) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Neurocrine Biosciences Inc (NBIX) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $18 billion, the company is a large-cap stock offering relative stability combined with growth potential.

Financial Performance Analysis

Our comprehensive financial analysis covers Neurocrine Biosciences Inc's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Neurocrine Biosciences Inc along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Neurocrine Biosciences Inc is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Neurocrine Biosciences Inc

Sign Up Free
Corporate Identity

Neurocrine Biosciences Inc (Stock Symbol: NBIX) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Neurocrine Biosciences Inc's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Neurocrine Biosciences Inc...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Neurocrine Biosciences Inc...

Unlock Full Company Profile

Get complete details about Neurocrine Biosciences Inc

Sign Up Free
Revenue & Growth Analysis

Neurocrine Biosciences Inc generates annual revenues of $3 billion , indicating a well-established business with proven market demand.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Neurocrine Biosciences Inc...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Neurocrine Biosciences Inc...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Neurocrine Biosciences Inc...

Unlock Financial Analysis

Get complete financial metrics for Neurocrine Biosciences Inc

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Neurocrine Biosciences Inc's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Neurocrine Biosciences Inc strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a large-cap market participant, the company has established significant competitive advantages and market presence. Large-cap companies typically benefit from brand recognition, operational scale, diverse revenue streams, and the financial resources to invest in research and development, marketing, and strategic acquisitions. This size category attracts substantial institutional ownership and analyst coverage.

Industry Competitive Landscape

Neurocrine Biosciences Inc competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company shows positive operational efficiency through free cash flow generation of $831 million annually . Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.

Asset Utilization Efficiency

Asset turnover ratio of 0.63x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.

Financial Strength & Leverage

Current ratio of 2.93 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Neurocrine Biosciences Inc (NBIX) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Neurocrine Biosciences Inc stock analysis.

Deep dive into Neurocrine Biosciences Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Neurocrine Biosciences Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Neurocrine Biosciences Inc: With a P/E ratio of 26.20, the market highly values future growth prospects.

P/E Ratio 26.20x
P/B Ratio 5.14x
Market Cap $17.52B
EPS $0.36
Book Value/Share $33.87
Revenue/Share $30.84
FCF/Share $8.26
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Neurocrine Biosciences Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Neurocrine Biosciences Inc: An ROE of 0.6% indicates room for improvement in shareholder value creation.

ROE 0.6%
ROA 0.4%
ROIC 0.3%
Operating Margin 12.3%
Net Margin 19.7%
EBT Margin 12.3%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Neurocrine Biosciences Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Neurocrine Biosciences Inc: A current ratio of 2.93 indicates strong liquidity.

Current Ratio 2.93x
Quick Ratio 2.85x
D/E Ratio 0.44x
Financial Leverage 1.44x
Interest Coverage -52.6x
Working Capital $1.60B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Neurocrine Biosciences Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Neurocrine Biosciences Inc: Free cash flow of $831M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow -$58M
Free Cash Flow $831M
Capital Spending $889M
FCF/Sales 26.8%
CapEx/Sales 28.7%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Neurocrine Biosciences Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Neurocrine Biosciences Inc: An asset turnover of 0.63x suggests room for improvement in asset utilization.

Asset Turnover 0.63x
Receivables Turnover 4.0x
Fixed Assets Turnover 34.1x
Days Sales Outstanding 90 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Neurocrine Biosciences Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Neurocrine Biosciences Inc: With annual revenue of $3102M, Neurocrine Biosciences Inc operates at significant scale.

Income Statement
Total Revenue $3.10B
Operating Income $12M
Net Income $19M
R&D Expense $62M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 2436%
Cash & Short-term Investments 267%
Total Liabilities 1499%
Short-term Debt 712%
Accounts Receivable 768%
Inventory 65%
Dividend & Shareholder Information
Shares Outstanding 101M
Growth Metrics (YoY)
Net Income Growth 19.7%
EPS Growth 0.2%

Latest Neurocrine Biosciences Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Neurocrine Biosciences Inc (NBIX) stock price and investment outlook.

📰 Loading...

Neurocrine Biosciences Inc Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Neurocrine Biosciences Inc against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $157M x 1.8x
ABPO ██% $1M x x
ACOG ██% $179M x 3.1x
ADAPY ██% $8M x x
ADMA ██% $1.94B 11.8x 5.0x
ADPT ██% $3.56B x 16.5x
AGEN ██% $238M 3.7x x
AGTX ██% $800K x x
AIM ██% $7M x 3.3x
ALEC ██% $165M x 15.9x
ALGS ██% $29M x 0.9x
ALLO ██% $628M x 2.3x
ALVO ██% $992M x x
AMGN ██% $200.50B 25.7x 21.8x
APGE ██% $10.05B x x
APTOF ██% $4M x x
ARGX ██% $57.22B x x
ARMP ██% $192M x x
ARTV ██% $492M x 5.6x
ATRA ██% $70M x x
ATYR ██% $49M x 0.8x
AURA ██% $745M x 6.9x
AUTL ██% $405M x 3.7x
AVXL ██% $230M x 1.8x
BCAB ██% $6M x x
BCDA ██% $14M x x
BCLI ██% $11M x x
BCRX ██% $2.38B x x
BDTX ██% $105M x 1.0x
BEAM ██% $2.66B x 2.3x
BIIB ██% $29.53B 21.5x 1.6x
BNTX ██% $23.28B x x
CABA ██% $444M x 4.3x
CADL ██% $722M x 5.2x
CCCC ██% $380M x 1.6x
CELZ ██% $5M x 0.9x
CERO ██% $500K x x
CGEM ██% $1.06B x 2.9x
CGEN ██% $221M 3.1x 2.2x
CGON ██% $6.26B x 5.7x
CGTX ██% $86M x 2.9x
CHRS ██% $221M 1.2x 2.8x
CLDI ██% $2M x 0.4x
CLLS ██% $279M x x
CMPX ██% $382M x 2.1x
CPMV ██% $5M x x
CRDF ██% $65M x 1.9x
CRDL ██% $123M x x
CRIS ██% $9M x 0.7x
CRSP ██% $4.58B x 2.5x
CSBR ██% $83M x 19.5x
CVM ██% $21M x 3.0x
DBVT ██% $820M x 5.1x
DNA ██% $489M x 1.1x
DNLI ██% $3.72B x 4.0x
DTIL ██% $189M x 2.5x
DYAI ██% $44M x x
EDIT ██% $419M x 95.0x
ELUT ██% $40M 0.8x 1.8x
ENGN ██% $127M x 0.5x
ENTX ██% $99M x 9.3x
ENZN ██% $59M x 0.3x
ESLA ██% $32M x x
EVAX ██% $25M x x
EXEL ██% $14.12B 16.9x 7.3x
EXOZ ██% $40M x 26.1x
FATE ██% $293M x 1.6x
FDMT ██% $543M x 1.2x
FENC ██% $351M x 9.3x
GILD ██% $162.53B 17.6x 6.9x
GLUE ██% $1.94B x 3.7x
GNTA ██% $80M x 6.4x
GPLB ██% $260K x x
GRML ██% $30M x 0.6x
HALO ██% $9.58B 27.5x 43.6x
HUMA ██% $172M x 14.8x
IBRX ██% $7.75B x x
IKT ██% $366M x 2.2x
IMA ██% $63M x 0.5x
IMCR ██% $1.81B x 4.6x
IMTX ██% $1.25B x x
IMVT ██% $8.03B x 9.4x
INAB ██% $12M x 0.5x
INKT ██% $50M x x
INMB ██% $46M x 2.3x
INTS ██% $11M x 1.1x
IOVA ██% $2.25B x 3.1x
IPSC ██% $391M x 1.5x
IVVD ██% $172M x 0.9x
JATT ██% $88M x 0.4x
JSPR ██% $24M x 7.1x
KLRS ██% $90M x 1.3x
KOD ██% $2.55B x 22.7x
KRYS ██% $9.64B 42.8x 7.6x
KYMR ██% $9.07B x 5.9x
KYTX ██% $441M x 2.3x
LCTX ██% $267M x 5.0x
LENZ ██% $158M x 0.6x
LIFE ██% $1.87B x 32.2x
LIMN ██% $7M x x
LONA ██% $68M x 1.4x
LXEO ██% $349M x 1.5x
MAZE ██% $1.53B x 4.5x
MESO ██% $2.09B x x
MGTX ██% $986M x x
MGX ██% $46M x 0.3x
MOLN ██% $160M x x
MRNA ██% $22.64B x 3.1x
NBIX ██% $17.52B 26.2x 5.1x
NMRA ██% $281M x 4.0x
NVAX ██% $1.29B x x
OCGN ██% $430M x 74.0x
OTLK ██% $247M x x
PALI ██% $338M x 2.7x
PASG ██% $16M x 1.3x
PCVX ██% $8.03B x 2.7x
PHGE ██% $2M x x
PLUR ██% $19M x x
PLX ██% $189M 12.3x 2.8x
PMCB ██% $6M x 0.2x
PRME ██% $536M x 7.0x
PROK ██% $459M x x
PTHS ██% $96M x 2.7x
QGEN ██% $8.99B x 2.4x
QNCX ██% $18M 2.1x 1.1x
REPL ██% $865M x 5.2x
RGEN ██% $7.76B 151.0x 3.7x
RGNX ██% $656M x 31.1x
RLAY ██% $4.14B x 6.5x
RVMD ██% $37.78B x 25.2x
RXRX ██% $1.60B x 1.6x
SABS ██% $274M x 1.2x
SANA ██% $866M x 7.3x
SCLX ██% $52M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $27M x x
SLDB ██% $804M x 2.2x
SLXN ██% $3M x 8.7x
SNTI ██% $13M x 5.2x
SRRK ██% $5.89B x 21.4x
SRZN ██% $231M x x
STRO ██% $391M x x
TARA ██% $226M x 1.3x
TARS ██% $2.52B x 7.2x
TCRX ██% $52M x 0.5x
TECH ██% $11.23B 102.5x 5.4x
TECX ██% $594M x 2.6x
TIL ██% $48M x 0.4x
TNYA ██% $168M x 1.6x
TSHA ██% $1.67B x 7.9x
TVGN ██% $18M x x
TWST ██% $5.75B x 12.6x
VACH ██% $541M 80.4x x
VALN ██% $488M x x
VCEL ██% $2.30B 107.1x 6.5x
VIR ██% $1.51B x 1.9x
VIVS ██% $2M x 0.4x
VOR ██% $1.03B x x
VXRT ██% $121M 3.3x 1.3x
VYGR ██% $186M x 1.1x
WINT ██% $340K x x
XFOR ██% $376M x 2.2x
ZEOX ██% $14M x 19.4x
ZIVO ██% $19M x x
ZURA ██% $502M x 2.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Neurocrine Biosciences Inc Stock Forecast

How accurate are Neurocrine Biosciences Inc stock predictions?

Our AI model shows a -19% Spearman correlation coefficient for NBIX predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Neurocrine Biosciences Inc stock price forecasts?

Our analysis considers Neurocrine Biosciences Inc's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Neurocrine Biosciences Inc a good investment in 2025?

Based on our AI analysis, Neurocrine Biosciences Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Neurocrine Biosciences Inc forecasts updated?

Neurocrine Biosciences Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Neurocrine Biosciences Inc?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...